Allworth Financial LP Supernus Pharmaceuticals, Inc. Transaction History
Allworth Financial LP
- $16.1 Billion
- Q3 2024
A detailed history of Allworth Financial LP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 40 shares of SUPN stock, worth $1,448. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40
Previous 40
-0.0%
Holding current value
$1,448
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SUPN
# of Institutions
282Shares Held
60.9MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$376 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$222 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$185 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$104 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$95.3 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.94B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...